Ekso Bionics (EKSO) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Ekso Bionics (NASDAQ:EKSO) announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.05), Bloomberg Earnings reports. Ekso Bionics had a negative return on equity of 323.00% and a negative net margin of 343.53%. The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.40 million.

Ekso Bionics (NASDAQ EKSO) traded up $0.04 during trading on Wednesday, hitting $1.96. The company had a trading volume of 884,700 shares, compared to its average volume of 1,113,267. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.09 and a quick ratio of 5.73. The company has a market cap of $117.41, a P/E ratio of -2.11 and a beta of 2.01. Ekso Bionics has a 1-year low of $0.99 and a 1-year high of $4.77.

In related news, insider Russ Angold sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $3.51, for a total transaction of $175,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.32% of the stock is owned by company insiders.

A hedge fund recently raised its stake in Ekso Bionics stock. Vanguard Group Inc. increased its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 32.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 711,082 shares of the company’s stock after buying an additional 176,197 shares during the quarter. Vanguard Group Inc. owned 2.77% of Ekso Bionics worth $1,650,000 at the end of the most recent reporting period. Institutional investors own 6.22% of the company’s stock.

Several analysts have recently weighed in on the company. Zacks Investment Research raised Ekso Bionics from a “sell” rating to a “hold” rating in a report on Tuesday. ValuEngine raised Ekso Bionics from a “strong sell” rating to a “sell” rating in a report on Friday, November 17th.

TRADEMARK VIOLATION WARNING: “Ekso Bionics (EKSO) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2017/11/09/ekso-bionics-holdings-inc-ekso-issues-earnings-results.html.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Earnings History for Ekso Bionics (NASDAQ:EKSO)

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit